Advancing The Purification Of VSV-G Pseudotyped Lentiviral Vector

Lentiviral (LV) vectors have emerged as a powerful tool in cell and gene therapy, offering several advantages over conventional retroviral delivery systems. Their ability to integrate into the host cell genome enables them to transduce both dividing and non-dividing cells, supporting stable and long-term gene expression. As the development pipeline for LV-based therapies expands, so too does the demand for scalable and efficient manufacturing processes that can reliably produce functional LV particles for clinical applications. However, despite significant progress in bioprocessing technologies, current production methods still suffer from substantial losses of biologically active vectors, posing a challenge to meeting clinical and commercial needs.

One promising solution to address this bottleneck lies in affinity chromatography, a technique that has successfully streamlined AAV purification through the development of specific affinity resins. For lentiviral vectors, however, the creation of a selective affinity ligand capable of binding the viral envelope — while maintaining biological activity during elution — has remained a key hurdle.

In this webinar, we introduce the CaptureSelect™ Lenti VSVG affinity matrix, designed specifically for the purification of VSV-G pseudotyped lentiviral particles from suspension cultures. Gain insights into the current challenges in LV purification, the development of this novel resin using CaptureSelect™ technology, and how it enables a scalable purification process with gentle elution conditions that preserve viral infectivity.